Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.
|Articles|January 1, 2004
HIFU continues to show promise in early PCa
Author(s)Alison Palkhivala
Montreal-High-intensity focused ultrasound (HIFU) continues to show promise for the local treatment of prostate cancer. When initiated early in the disease, the minimally invasive procedure offers good efficacy results with little morbidity, according to several European studies presented at the World Congress on Endourology here.
Advertisement
Advertisement
Related to this article
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
4
Engy Habashy, MD, on the role of androgens in GSM management
5